Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:36:34 2024-05-20 pm EDT			5-day change	1st Jan Change
20.4 ^USD	+0.52%		-2.91%	-5.78%

May. 16	Transcript : Syndax Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM
May. 15	Syndax Pharmaceuticals, Inc. Announces Board Changes	CI

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

May 09, 2024 at 07:01 am EDT

WALTHAM, Mass., May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-bank-of-america-securities-2024-health-care-conference-302140895.html

SOURCE Syndax Pharmaceuticals, Inc.

Latest news about Syndax Pharmaceuticals, Inc.

Transcript : Syndax Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM	May. 16
Syndax Pharmaceuticals, Inc. Announces Board Changes	May. 15	CI
Syndax Pharmaceuticals Q1 Net Loss Widens	May. 08	MT
Transcript : Syndax Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	Apr. 08	CI
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	Mar. 28	CI
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	Mar. 26	MT
Syndax Says Revumenib NDA Granted FDA Priority Review	Mar. 26	DJ
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia	Mar. 26	CI
JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	Mar. 20	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	Mar. 18	MT
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer	Mar. 18	MT
Syndax Pharmaceuticals, Inc. Announces Executive Changes	Mar. 18	CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM	Mar. 12
Transcript : Syndax Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 11:00 AM	Feb. 21
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024.	Feb. 12	CI
Certain Stock Options of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024.	Feb. 12	CI
Certain Pre-Funded Warrants of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024.	Feb. 12	CI
Certain Common Stock of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024.	Feb. 12	CI
North American Morning Briefing : Stock Futures -2-	Feb. 01	DJ
Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform From Sector Outperform, Cuts Price Target to $23 From $36	Jan. 31	MT

Chart Syndax Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.29 USD

Average target price

34.17 USD

Spread / Average Target

+68.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYNDAX PHARMACEUTICALS, INC.	-5.78%	1.72B
MODERNA, INC.	+41.19%	50.93B
IQVIA HOLDINGS INC.	-0.38%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.73%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.44%	18.9B
BIO-TECHNE CORPORATION	+7.34%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.69%	12.17B
MEDPACE HOLDINGS, INC.	+30.49%	12.16B

Other Biotechnology & Medical Research